Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results.
about
Current Trends of Renal Impairment in Multiple MyelomaTreatment of autologous stem cell transplant-eligible multiple myeloma patients: ten questions and answersMolecular pathogenesis of multiple myeloma: basic and clinical updatesCost-effectiveness of bortezomib for multiple myeloma: a systematic reviewOptimal maintenance and consolidation therapy for multiple myeloma in actual clinical practiceProof of the concept to use a malignant B cell line drug screen strategy for identification and weight of melphalan resistance genes in multiple myelomaThe varied distribution and impact of RAS codon and other key DNA alterations across the translocation cyclin D subgroups in multiple myelomaHow we manage autologous stem cell transplantation for patients with multiple myelomaImmunomodulatory drugs in multiple myeloma.Genome-wide association study identifies multiple susceptibility loci for multiple myeloma.Coexistent hyperdiploidy does not abrogate poor prognosis in myeloma with adverse cytogenetics and may precede IGH translocationsMinimal residual disease in myeloma by flow cytometry: independent prediction of survival benefit per log reductionHaematopoietic stem cell transplantation as first-line treatment in myeloma: a global perspective of current concepts and future possibilitiesA gene expression based predictor for high risk myeloma treated with intensive therapy and autologous stem cell rescue.Thalidomide treatment for patients with previously untreated multiple myeloma: a meta-analysis of randomized controlled trials.European perspective on multiple myeloma treatment strategies: update following recent congressesMolecular pathogenesis of multiple myeloma and its premalignant precursor.Genome-wide association study identifies variation at 6q25.1 associated with survival in multiple myeloma.Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma.The genetic and genomic background of multiple myeloma patients achieving complete response after induction therapy with bortezomib, thalidomide and dexamethasone (VTD)Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group.Guidelines on the diagnosis and management of multiple myeloma treatment: Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular Project guidelines: Associação Médica Brasileira - 2012Is it feasible to use granulocyte-colony stimulating factor alone to mobilize progenitor cells in multiple myeloma patients induced with a cyclophosphamide, thalidomide and dexamethasone regimen?Efficacy and toxicity of the combination chemotherapy of thalidomide, alkylating agent, and steroid for relapsed/refractory myeloma patients: a report from the Korean Multiple Myeloma Working Party (KMMWP) retrospective study.Outcomes of autologous transplantation for multiple myeloma according to different induction regimensThe Singapore Myeloma Study Group Consensus Guidelines for the management of patients with multiple myeloma.Comment on "Outcomes of autologous transplantation for multiple myeloma according to different induction regimens".Current therapeutic strategy for multiple myeloma.Current approaches for the treatment of multiple myeloma.Diagnosis and therapy of multiple myeloma.Therapeutic effects of thalidomide in hematologic disorders: a review.Frontline therapy for multiple myeloma: a concise review of the evidence based on randomized clinical trials.International Myeloma Working Group recommendations for global myeloma care.Initial treatment of transplant-eligible patients in multiple myeloma.The emerging role of carfilzomib combination therapy in the management of multiple myeloma.Maintenance therapy in newly diagnosed multiple myeloma: current recommendations.The impact of intra-clonal heterogeneity on the treatment of multiple myeloma.The potential of miRNAs as biomarkers for multiple myeloma.The role of pre-transplant induction regimens and autologous stem cell transplantation in the era of novel targeted agents.Current therapeutic strategies for multiple myeloma.
P2860
Q26740444-DB22EAB3-DF9C-4F29-98EC-593E8AECAF80Q26851202-C307040C-BB2D-47D4-AFD9-BAD3B8F31430Q27026205-77FD1E78-8837-4024-A30C-C1BDB8F0CDE6Q28075297-4A864E34-653C-4F1C-808E-8FF90E4A4385Q28077567-028BF671-0E8B-4CEE-84CC-D0116A70E737Q28537857-81AA5129-F409-468B-960C-C9BFCAABC117Q33709470-D12851B2-E371-48E1-91CD-920B7E1C20BEQ34019581-F6825A61-62E9-4BC6-9FB7-99B65030C46BQ34325722-4B2DF396-AF37-4C29-A2D1-4EEFE769DB11Q34677689-0E512034-4FC2-4D43-8FEA-048868E4EC03Q35081172-6FA25154-D54E-485E-B6B4-27739B3DBC65Q35222117-11C1A443-5742-4B5C-A95F-2E8306139FD4Q35569350-4409F6C3-8854-4B67-814D-6156FFFF3533Q35651050-9A135B5E-E97C-49AB-91B3-E21C734BCE99Q35932505-6DC6F214-3739-4C06-A9CA-F95E82E61412Q35989943-AC5D1624-7C48-4411-B8EF-86E4478814A6Q36290238-E5F6265E-6FA9-4825-924B-D654EE0DCD70Q36511162-E360D28F-C8C6-4302-B929-956C86995F4FQ36595290-07D72602-F181-41A1-909E-99573791B7AFQ36962747-5AB47AEE-0117-4EEE-A975-DE302A05495DQ37037265-BDD33751-D1E6-4D1B-AE6A-4F0BFB5A4B80Q37057028-B424EA90-A607-4B48-B99E-081481BC1EBBQ37429248-2C45D3D0-BA4B-45DC-BB7F-FC258915A9A3Q37609489-738CBF44-E027-4FF0-99C0-4CE1F9EE685EQ37628609-9B663411-8DCE-4524-9DE3-D3D695F81A61Q37644252-B8BB17DF-EB32-40E9-8CFE-AC45B67D782DQ37734031-0C30A27C-06BD-454C-AC63-487CF9E85B89Q38072022-228205CA-1769-47CF-88FA-1A4210B99818Q38087939-D22376FE-487B-40C7-9F37-EF85CC365610Q38107482-06E442E8-A16A-49A3-8F7B-4809234F559BQ38121762-03F6855B-8EFF-43A7-90C3-5CC570F9D7A5Q38148272-0297D348-9FFC-451B-B472-F53931B6B35BQ38157532-E83DB092-01C8-447A-A578-F4A743A9F654Q38176061-8E9C1382-15BF-4D8D-840B-76661C467D65Q38187476-6F2C7994-F8C6-4043-96A8-390BC3D23DBEQ38191975-4ECB9E8B-D315-45D9-8355-0C1406F57381Q38192044-14F4C869-6B41-4377-B2A7-54A18C3AB9E3Q38237446-140ECCF3-65DD-4366-AEB6-9307FE4645CAQ38375463-61B082CC-0A8C-4097-B3A6-D6FE0BB631ABQ38412189-4D158E72-8DBD-4A23-81BA-E0BE4EE76805
P2860
Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Cyclophosphamide, thalidomide, ...... a IX randomized trial results.
@ast
Cyclophosphamide, thalidomide, ...... a IX randomized trial results.
@en
type
label
Cyclophosphamide, thalidomide, ...... a IX randomized trial results.
@ast
Cyclophosphamide, thalidomide, ...... a IX randomized trial results.
@en
prefLabel
Cyclophosphamide, thalidomide, ...... a IX randomized trial results.
@ast
Cyclophosphamide, thalidomide, ...... a IX randomized trial results.
@en
P2093
P2860
P1433
P1476
Cyclophosphamide, thalidomide, ...... a IX randomized trial results.
@en
P2093
Alexander J Szubert
Claudius Rudin
Faith E Davies
Fiona M Ross
Gareth J Morgan
Gordon Cook
Graham H Jackson
J Anthony Child
Mark T Drayson
National Cancer Research Institute Haematological Oncology Clinical Studies Group
P2860
P304
P356
10.3324/HAEMATOL.2011.043372
P577
2011-11-04T00:00:00Z